C

Corline Biomedical AB
STO:CLBIO

Watchlist Manager
Corline Biomedical AB
STO:CLBIO
Watchlist
Price: 17 SEK -1.16% Market Closed
Market Cap: 416.3m SEK

Corline Biomedical AB
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Corline Biomedical AB
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
C
Corline Biomedical AB
STO:CLBIO
EPS (Diluted)
kr0
CAGR 3-Years
N/A
CAGR 5-Years
-12%
CAGR 10-Years
-10%
Calliditas Therapeutics AB
STO:CALTX
EPS (Diluted)
-kr8
CAGR 3-Years
9%
CAGR 5-Years
-56%
CAGR 10-Years
N/A
Orexo AB
STO:ORX
EPS (Diluted)
-kr5
CAGR 3-Years
-10%
CAGR 5-Years
N/A
CAGR 10-Years
-8%
Camurus AB
STO:CAMX
EPS (Diluted)
kr12
CAGR 3-Years
200%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Swedencare AB (publ)
STO:SECARE
EPS (Diluted)
kr0
CAGR 3-Years
-12%
CAGR 5-Years
1%
CAGR 10-Years
N/A
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
EPS (Diluted)
-kr3
CAGR 3-Years
-176%
CAGR 5-Years
-63%
CAGR 10-Years
N/A
No Stocks Found

Corline Biomedical AB
Glance View

Market Cap
416.3m SEK
Industry
Pharmaceuticals

Corline Biomedical AB engages in the research, development, and commercialization of heparin based solutions. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2015-06-03. The company develops, manufactures and markets heparin-based solutions to improve kidney transplantation, cell therapies and applications in regenerative medicine.

CLBIO Intrinsic Value
26.47 SEK
Undervaluation 36%
Intrinsic Value
Price
C

See Also

What is Corline Biomedical AB's EPS (Diluted)?
EPS (Diluted)
-1 SEK

Based on the financial report for Sep 30, 2025, Corline Biomedical AB's EPS (Diluted) amounts to -1 SEK.

What is Corline Biomedical AB's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
-10%

Over the last year, the EPS (Diluted) growth was -116%.

Back to Top